Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells

Conclusion: Chemo-endocrine combination therapy using S-1 and fulvestrant is beneficial in estrogen-responsive breast cancer.

Source: In Vivo - August 29, 2019 Category: Research Authors: NUKATSUKA, M., SAITO, H., NOGUCHI, S., TAKECHI, T. Tags: Experimental Studies Source Type: research